Lawsuit filed for Investors who lost money with shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO)

An investor, who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO), filed a lawsuit over alleged violations of Federal Securities Laws by Zenas BioPharma, Inc. in connection with certain allegedly false and misleading statements made in connection with Zenas BioPharma's September 2024 initial public offering (the "IPO").

Investors who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) have certain options and for certain investors are short and strict deadlines running. Deadline: June 16, 2025. NASDAQ: ZBIO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Waltham, MA based Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Zenas BioPharma, Inc. (NASDAQ: ZBIO

Zenas BioPharma, Inc. completed its initial public offering (IPO) on September 13, 2024, listing on the Nasdaq Global Select Market under the ticker symbol ZBIO. The company raised approximately $225 million in the offering, with an implied valuation of $710 million. They sold 13.2 million shares at $17 per share. After the full exercise of the underwriters' option to purchase additional shares, they sold a total of 15,220,588 shares, resulting in gross proceeds of approximately $258.7 million.

However, since the IPO shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) declined to as low as $5.83 per share on January 28, 2025.

The plaintiff claims that the Registration Statement that was filed in connection with Zenas BioPharma's September 2024 IPO contained false and/or misleading statements and/or failed to disclose that Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO, and that as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared.

Those who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.